Dear Arturo,
Here are some references:
Hormone replacement therapy. Drug Ther Bull 1996;34:81-5
This carries a lot of references.
Corticosteroid-induced osteoporosis. Drug Ther Bull 1996;34:84-7
Peel N, Eastell R. Osteoporosis. BMJ 1995;310:989-92
Eastell R. Management of corticosteroid-induced osteoporosis. J Intern Med
1995;237:439-47
New drugs for osteoporosis. Med Letter 1996;38:1-3
Alendronate: a new treatment for osteoporosis. Int Pharm J 1996;10:99-101
Original in a newsletter from Medicines Resource Centre, UK
"Pill esophagitis" - the case of alendronate. New Engl J Med 1996;335:1058-9
Esophagitis and alendronate. New Engl J Med 1996;335:1069-70
Drife, JO. Benefits and risks of hormone replacement therapy - an update.
Adverse Drug Reactions Bulletin 1994;no 166:627-30
Osteoporosis: Who should be treated? Am J Med 1995;98 Suppl 2A
JAMA 1996;276 no 17 carries many articles on bone density etc.
Editorial: Boning up on estrogen: New options, new concerns pg 1430
MacLennan AH, Smith M. Hormone replacement therapy and breast cancer: what
are the facts? Med J Aust 1995;163:483-5
Davidson NE. Hormone-replacement therapy - breast versus heart versus bone.
New Engl J Med 1995;332:1639-9
Colditz GA et al. The use of estrogens and progestins and the risk of breast
cancer in postmenopausal women. New Engl J Med 1995;332:1589-93
Patel S et al. Drugs used in the treatment of metabolic bone disease.
Clinical pharmacology and therapeutic use. Drugs 1993;46:594-617
Marshall D et al. Metanalysis of how well measures of bone mineral density
predict occurence of osteoporotic fractures. BMJ 1996;312:1254-9
These are some of the references I have collected. As you see I have a
particular interest in the subject as it is "in the family". My mother is
taking intranasal calcitonin with very good effect and no side effects.
Please let me know if you would like copies of any of the articles.
Best regards Kirsten
Ms Kirsten Myhr, MScPharm, MPH
Bygdoy Alle 58B
0265 Oslo
Norway
Tel: +47 22 56 05 85 (h)
Fax: +47 22 24 90 17 (w) Tel: +47 22 24 90 39 (w)
E-mail: myhr@online.no
or (w): kirsten.myhr@helsetilsynet.dep.telemax.no
--
Send mail for the `E-Drug' conference to `e-drug@usa.healthnet.org'.
Mail administrative requests to `majordomo@usa.healthnet.org'.
For additional assistance, send mail to: `owner-e-drug@usa.healthnet.org'.